Las Vegas, USA, April 25, 2022 (GLOBE NEWSWIRE) -- HER2 negative Breast Cancer Pipeline Insights | Research Report 2022 by DelveInsight
HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously working towards developing 85+ HER2 negative Breast Cancer treatment therapies, as per DelveInsight
DelveInsight’s HER2 negative Breast Cancer Pipeline Insight 2021 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain.
Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report:
- DelveInsight’s HER2 negative Breast Cancer Pipeline analysis depicts a robust space with 85+ active players working to develop 85+ pipeline treatment therapies.
- Some of the key pharmaceutical companies working to develop potential drug candidates to improve the HER2 negative Breast Cancer treatment scenario include BeiGene, Olema Pharmaceuticals, AstraZeneca, Radius Health, Adagene Inc, H3 Biomedicine Inc., Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., OncoSec Medical Incorporated, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pfizer, InventisBio Co., Ltd, Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisai Co., Ltd., Context Therapeutics, Boehringer Ingelheim, CytomX Therapeutics, Beta Pharma (Suzhou) Co., Ltd., Eli Lilly and Company, Laekna Limited, Sermonix Pharmaceuticals Inc., Modra Pharmaceuticals, MedImmune LLC, QED Therapeutics, Inc., Tyme, Inc., PIQUR Therapeutics, Pfizer, Merus N.V., Seagen, Relay Therapeutics, Inc., Blueprint Medicines Corporation, TransThera Sciences (Nanjing), Inc., HUTCHMED, VelosBio Inc., Dantari, Inc., GlaxoSmithKline, G1 Therapeutics, Inc., Spectrum Pharmaceuticals, Inc, Taizhou EOC Pharma Co., Ltd., Xuanzhu Biopharmaceutical Co., Ltd., Regor Pharmaceuticals Inc, Astex Pharmaceuticals, Inc., Kind Pharmaceuticals LLC, Genor Biopharma Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd., Nerviano Medical Sciences, Tolmar Inc., Zeno Alpha Inc., Accutar Biotechnology Inc, Jiangsu Hansoh Pharmaceutical Co., Ltd., Zenith Epigenetics, Cantargia, BioLite, Inc., PharmAbcine, Ayala Pharmaceuticals, Inc., ERYtech Pharma, SynCore Biotechnology Co., Ltd., Phoenix Molecular Designs, Chipscreen Biosciences, Ltd., OncoTherapy Science, Inc., OncoPep, Inc., and many others.
- Essential HER2 negative Breast Cancer pipeline therapies such as BGB-290, OP-1250, AZD9833, Elacestrant, ADG106, H3B-6545, Dato-DXd, HRS8807, TAVO, Mitoxantrone Hydrochloride, Gedatolisib, D-0502, Ipatasertib, ANG1005, Nivolumab, Ipilimumab, Lenvatinib, Onapristone, Xentuzumab, CX-2009, BPI-1178, LY3484356, Afuresertib, Lasofoxifene, ModraDoc006/r, MEDI4736, Infigratinib, SM-88, PQR309, PF-07248144, MCLA-128, SGN-CD228A, RLY-2608, BLU-222, TT-00420, HMPL-013, Zilovertamab vedotin, DAN-222, Niraparib, G1T38, Poziotinib Hydrochloride, EOC202, XZP-3287, RGT-419B, ASTX727, AND019, Lerociclib, SGN-STNV, SCR-6852, NMS-03305293, TOL2506, ZN-c5, AC682, HS-10342, ZEN003694, Nadunolimab, BLEX 404, Olinvacimab, AL101, eryaspase, EndoTAG-1, PMD-026, Chiauranib, OTS167PO, PVX-410, and others are under development in different phases of clinical trials.
- In January 2022, Celcuity announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation to the Company's lead drug candidate, gedatolisib, for the treatment of patients with HR+/HER2- metastatic breast cancer after progression on CDK4/6 therapy.
- In December 2021, H3 Biomedicine Inc. (H3), announced the presentation of two posters at the 2021 San Antonio Breast Cancer Symposium (SABCS) being held in a hybrid format on December 7- 10, 2021. The presentations include interim investigational data from H3’s ongoing clinical development program, H3B-6545, a potential first-in-class, orally available Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer.
- The investigational oral selective estrogen receptor degrader (SERD) elacestrant significantly decreased the risk of death or disease progression and increased progression-free survival compared with standard-of-care endocrine therapy for postmenopausal patients with estrogen receptor (ER)-positive/HER2-negative metastatic breast cancers that progressed on prior endocrine and targeted therapies, according to results from the phase III EMERALD trial, which were presented at the San Antonio Breast Cancer Symposium, held December 7-10, 2021.
- In November 2021, Olema Pharmaceuticals, Inc. announced the first clinical data from the Phase 1 dose-escalation portion of the ongoing Phase 1/2 clinical trial of OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) in development for the treatment of metastatic breast cancer and other women’s cancers.
Request a sample and discover more about the report offerings @ HER2 negative Breast Cancer Emerging Therapies
The HER2 negative Breast Cancer pipeline report lays down detailed profiles of the pipeline assets, comparative analysis of clinical and non-clinical stage HER2 negative Breast Cancer products, inactive and dormant assets, comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the HER2 negative Breast Cancer pipeline landscape.
HER2 negative Breast Cancer Overview
Most Breast Cancers express the Estrogen Receptor (ER) receptor and are negative for the human epidermal growth factor receptor 2 (HER2) receptor. ER+/ HER2 – ve Breast Cancer includes tumors that are ER-positive and PR positive, but negative for HER2. ER+/ HER2 – ve Breast Cancer is heterogeneous and accounts for about 70% of all breast cancers. HER2” stands for human epidermal growth factor receptor 2. There are various types of breast cancer, some have hormone receptors like estrogen or progesterone (some have both) and are called ER+ or PR+ breast cancer respectively.
Find out more about the disease and recent developments @ HER2 negative Breast Cancer Pipeline Assessment
HER2 negative Breast Cancer Pipeline Drugs
| Drug | Company | Phase | MoA | RoA |
| BGB-290 | BeiGene | Phase II | Poly(ADP-ribose) polymerase 1 inhibitors | Oral |
| OP-1250 | Olema Pharmaceuticals, Inc. | Phase I/II | Estrogen receptor antagonists | Oral |
| AZD9833 | AstraZeneca | Phase III | Selective estrogen receptor degraders | Oral |
| ADG106 | Adagene Inc | Phase I/II | CD137 antigen agonists | Intravenous |
| Dato-DXd | Daiichi Sankyo, Inc. | Phase III | DNA topoisomerase I inhibitors | Intravenous |
| HRS8807 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase I | NA | NA |
| Ipatasertib | Genentech | Phase III | Proto oncogene protein c-akt inhibitors | Oral |
| CX-2009 | CytomX Therapeutics | Phase II | Apoptosis stimulants | Intravenous |
| BPI-1178 | Beta Pharma (Suzhou) Co., Ltd. | Phase I/II | Cyclin-dependent kinase 4 inhibitors | Oral |
Learn more about the novel and emerging HER2 negative Breast Cancer pipeline therapies @ HER2 negative Breast Cancer Pipeline Analysis
HER2 negative Breast Cancer Therapeutics Assessment
The HER2 negative Breast Cancer Pipeline report proffers an integral view of the HER2 negative Breast Cancer emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.
Scope of the HER2 negative Breast Cancer Pipeline Report
- Coverage: Global
- Therapeutic Assessment By HER2 negative Breast Cancer Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By HER2 negative Breast Cancer Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Pre-registration, Inactive candidates
- Therapeutics Assessment By HER2 negative Breast Cancer Therapeutics Route of Administration: Oral, Intravenous, Inhalation, Subcutaneous
- Therapeutics Assessment By HER2 negative Breast Cancer Therapies Molecule Type: Gene therapy, Stem cell therapy, Small molecules
- Therapeutics Assessment By HER2 negative Breast Cancer Therapies Mechanism of Action: Selective estrogen receptor degrader, Estrogen receptor alpha antagonist, Phosphoinositide 3-kinase (PI3K) inhibitor, Selective estrogen receptor degraders
- Key HER2 negative Breast Cancer Companies: BeiGene, Olema Pharmaceuticals, AstraZeneca, Radius Health, Adagene Inc, H3 Biomedicine Inc., Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., OncoSec Medical Incorporated, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pfizer, InventisBio Co., Ltd, Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisai Co., Ltd., Context Therapeutics, Boehringer Ingelheim, CytomX Therapeutics, Beta Pharma (Suzhou) Co., Ltd., Eli Lilly and Company, Laekna Limited, Sermonix Pharmaceuticals Inc., Modra Pharmaceuticals, MedImmune LLC, QED Therapeutics, Inc., Tyme, Inc., PIQUR Therapeutics, Pfizer, Merus N.V., Seagen, Relay Therapeutics, Inc., Blueprint Medicines Corporation, TransThera Sciences (Nanjing), Inc., HUTCHMED, VelosBio Inc., Dantari, Inc., GlaxoSmithKline, G1 Therapeutics, Inc., Spectrum Pharmaceuticals, Inc, Taizhou EOC Pharma Co., Ltd., Xuanzhu Biopharmaceutical Co., Ltd., Regor Pharmaceuticals Inc, Astex Pharmaceuticals, Inc., Kind Pharmaceuticals LLC, Genor Biopharma Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd., Nerviano Medical Sciences, Tolmar Inc., Zeno Alpha Inc., Accutar Biotechnology Inc, Jiangsu Hansoh Pharmaceutical Co., Ltd., Zenith Epigenetics, Cantargia, BioLite, Inc., PharmAbcine, Ayala Pharmaceuticals, Inc., ERYtech Pharma, SynCore Biotechnology Co., Ltd., Phoenix Molecular Designs, Chipscreen Biosciences, Ltd., OncoTherapy Science, Inc., OncoPep, Inc., and many others.
- Key HER2 negative Breast Cancer Pipeline Therapies: BGB-290, OP-1250, AZD9833, Elacestrant, ADG106, H3B-6545, Dato-DXd, HRS8807, TAVO, Mitoxantrone Hydrochloride, Gedatolisib, D-0502, Ipatasertib, ANG1005, Nivolumab, Ipilimumab, Lenvatinib, Onapristone, Xentuzumab, CX-2009, BPI-1178, LY3484356, Afuresertib, Lasofoxifene, ModraDoc006/r, MEDI4736, Infigratinib, SM-88, PQR309, PF-07248144, MCLA-128, SGN-CD228A, RLY-2608, BLU-222, TT-00420, HMPL-013, Zilovertamab vedotin, DAN-222, Niraparib, G1T38, Poziotinib Hydrochloride, EOC202, XZP-3287, RGT-419B, ASTX727, AND019, Lerociclib, SGN-STNV, SCR-6852, NMS-03305293, TOL2506, ZN-c5, AC682, HS-10342, ZEN003694, Nadunolimab, BLEX 404, Olinvacimab, AL101, eryaspase, EndoTAG-1, PMD-026, Chiauranib, OTS167PO, PVX-410, and others.
Dive deep into rich insights for emerging therapies and assessment, visit @ HER2 negative Breast Cancer Emerging Therapies
Table of Contents
| 1 | Introduction |
| 2 | Executive Summary |
| 3 | HER2 negative Breast Cancer: Overview |
| 4 | Pipeline Therapeutics |
| 5 | Late Stage Products (Phase III) |
| 5.1 | Dato-DXd: Daiichi Sankyo, Inc. |
| 6 | Mid Stage Products (Phase II) |
| 6.1 | CX-2009: CytomX Therapeutics |
| 7 | Early Stage Products (Phase I/II) |
| 7.1 | BPI-1178: Beta Pharma (Suzhou) Co., Ltd. |
| 8. | Therapeutic Assessment |
| 9 | Inactive Products |
| 10 | Collaborations Assessment- Licensing / Partnering / Funding |
| 11 | HER2 negative Breast Cancer- Unmet Needs |
| 12 | HER2 negative Breast Cancer- Market Drivers and Barriers |
| 13 | Appendix |
| 14 | About DelveInsight |
For further information on the HER2 negative Breast Cancer current pipeline therapeutics, reach out @ HER2 negative Breast Cancer Ongoing Clinical Trials
Related Reports
DelveInsight’s ‘Breast Pumps - Market Insight, Competitive Landscape and Market Forecast, 2026’ report delivers an in-depth understanding of Breast Pumps and the historical and forecasted Breast Pumps market trends, globally, which comprises North America, Europe, APAC, and RoW.
Metastatic Breast Cancer Pipeline
DelveInsight’s, “Metastatic Breast Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Metastatic Breast Cancer pipeline landscape. It covers the pipeline drug profiles and key companies involved like Roche, RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Hengrui Medicine Co, Tyme, Inc, Orion Pharma, HiberCell, Inc, Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc, and others.
Hormone Receptor (HR) positive/Human Epidermal Receptor 2 (HER2) negative Breast Cancer Market
DelveInsight’s ‘Hormone Receptor (HR) positive/ Human Epidermal Receptor 2 (HER2) negative Breast Cancer-Market Insights, Epidemiology and Market Forecast–2030’ report delivers an in-depth understanding of the HR-positive/ HER2-negative breast cancer, historical and forecasted epidemiology current treatment practices, emerging drugs, and key companies involved like Pfizer, Novartis, AstraZeneca, Eli Lilly, Jiangsu HengRui Medicine Co, Odonate Therapeutics, Radius Pharmaceuticals, Immunomedics, and many others.
Triple-Negative Breast Cancer Market
DelveInsight's "Triple Negative Breast Cancer (TNBC) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Triple Negative Breast Cancer (TNBC), historical and forecasted epidemiology, market share of the individual therapies, and key companies involved like Merck, Roche, CytoDyn, Infinity, Treadwell Therapeutics, and many more.
Hormone Receptor (HR) positive/ Human Epidermal Receptor 2 (HER2) negative Breast Cancer Market
DelveInsight’s ‘Hormone Receptor (HR) positive/ Human Epidermal Receptor 2 (HER2) negative Breast Cancer-Market Insights, Epidemiology and Market Forecast–2030’ report delivers an in-depth understanding of the HR-positive/ HER2-negative breast cancer, historical and forecasted epidemiology, market drivers, market barriers and key companies involved like Pfizer, Novartis, AstraZeneca Pharmaceuticals, Eli Lilly, Jiangsu HengRui Medicine Co., Odonate Therapeutics, Radius Pharmaceuticals, Immunomedics, and many others.
ESR1 Mutated Metastatic Breast Cancer Epidemiology
DelveInsight’s ‘ESR1 Mutated Metastatic Breast Cancer - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the ESR1 Mutated Metastatic Breast Cancer, historical and forecasted epidemiology as well as the ESR1 Mutated Metastatic Breast Cancer epidemiology trends.
Inflammatory breast cancer Epidemiology
DelveInsight's "Inflammatory breast cancer - Epidemiology Forecast to 2030" report delivers an in-depth understanding of the disease, historical and forecasted Inflammatory breast cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Interested to know more about the breakthrough happenings? Take a look at the posts below
- 7 Most Common Myths About Breast Cancer Demystified
- Key Facts About Triple-Negative Breast Cancer During The Breast Cancer Awareness Month
- Breast Cancer: Understand your breasts, recognize the symptoms
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
